Proton Pump Inhibitors

1. Front Matter

   Pages I-X

   PDF

2. The discovery and development of the proton pump inhibitor

   1. Front Matter

      Pages 1-1

      PDF

   2. The discovery and development of the proton pump inhibitor

      • Sven Erik Sjöstrand, Lars Olbe, Erik Fellenius

      Pages 3-20

3. Mechanism of Action

   1. Front Matter

      Pages 21-21

      PDF

   2. The gastric H, K ATPase

      • George Sachs, Björn Wallmark

      Pages 23-45

   3. Inhibition of the gastric proton pump

      • Björn Wallmark, George Sachs

      Pages 47-59

4. The Pharmacology of Proton Pump Inhibitors

   1. Front Matter

      Pages 61-61

      PDF

   2. Inhibition of gastric acid secretion

      • Jia-Qing Huang, Richard H. Hunt

      Pages 63-78

   3. Consequences of gastric acid inhibition in animals

      • Enar Carlsson, Niilo Havu

      Pages 79-89

   4. Consequences of gastric acid inhibition in man

      • Werner Creutzfeldt

      Pages 91-115

   5. The acid tolerance of Helicobacter pylori

      • George Sachs, David Scott, David Wecks, Klaus Melchers

      Pages 117-130

   6. Interactions of proton pump inhibitors and Helicobacter pylori in vivo

      • Andre Louis Blum, Jan Martinek

      Pages 131-141

   7. Comparison of different proton pump inhibitors

      • Karl-Uwe Petersen

      Pages 143-157

5. Pharmaceutical considerations

   1. Front Matter

      Pages 159-159

      PDF

   2. Pharmaceutical considerations

      • Åke G. Pilbrant

      Pages 161-169

6. Clinical Experience with Proton Pump Inhibitors

   1. Front Matter

      Pages 171-171

      PDF

   2. Helicobacter pylori infection and peptic ulcer disease

      • Peter Malfertheiner

      Pages 173-191

   3. Non-Steroidal anti-inflammatory drug-associated ulcers

      • C. J. Hawkey

      Pages 193-203

   4. Zollinger-Ellison syndrome

      • Robert T. Jensen

      Pages 205-221

   5. Gastro-oesophageal reflux disease

      • Lars Lundell, John Dent

      Pages 223-235

Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi­ bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be­ tween efficacy and safety of a new drug. This goal often involves time and many different specialists.

• diseases
• drug
• helicobacter pylori
• pharmacology
• quality of life
• research
• therapy

• Centre for Gastroenterological Research, University of Göteborg, Göteborg, Sweden

  Lars Olbe

Policies and ethics